Stockscreener 앱 받기
9.23
4.15%
-0.40
시간 외 거래:
9.19
-0.04
-0.43%
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Dow Dips Around 300 Points As Israel-Iran Conflict Escalates: Investor Sentiment Declines, Fear & Greed Index Moves To 'Neutral' Zone - Benzinga
CERo Therapeutics stock soars after FDA grants Orphan Drug Designation By Investing.com - Investing.com India
CERo Therapeutics stock soars after FDA grants Orphan Drug Designation - Investing.com
Sector Update: Health Care - MarketScreener
Crude Oil Rises Sharply; Jabil Earnings Top Views - Benzinga
CERo Therapeutics (CERO) Stock Explodes Over 200% in a Landmark Trading Day - Daily Chhattisgarh News
CERO Trading Halted Due to Market Volatility | CERO Stock News - GuruFocus
CERo Therapeutics Says CER-1236 Gets FDA Orphan Drug Designation in Acute Myeloid Leukemia - marketscreener.com
US Stocks Lower; Retail Sales Decline In May - Benzinga
CERO Trading Resumes: Key Developments and Insights | CERO Stock News - GuruFocus
What's Going On With Cero Therapeutics Stock Tuesday? - Benzinga
Cero Therapeutics announces FDA ODD granted to CER-1236 - TipRanks
CERo Therapeutics Gains FDA Orphan Drug Designation - TipRanks
CERo Therapeutics Gets Orphan Drug Status For CER-1236 In Acute Myeloid Leukemia - Nasdaq
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug - GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) - Yahoo
FDA Grants Orphan Status to CeroTherapeutics' Acute Myeloid Leukemia Drug | CERO Stock News - GuruFocus
Cero Therapeutics treatment of leukemia granted orphan designation - TipRanks
CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements - TipRanks
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 - MSN
Trading Halted for CERO; Anticipated Announcement Pending | CERO Stock News - GuruFocus
Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance
CERO Announces One-for-Twenty Reverse Stock Split | CERO Stock N - GuruFocus
CERo Therapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com South Africa
CERo Therapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
CERo Therapeutics Announces Reverse Stock Split - TipRanks
CERo Therapeutics Holdings, Inc. Announces One-for-Twenty Reverse Stock Split Effective June 13, 2025 - Nasdaq
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire
CERo Therapeutics Sets Major 1:20 Reverse Split, Shares Consolidate 95% Next Week - Stock Titan
CERo Therapeutics issues additional Series D stock By Investing.com - Investing.com South Africa
CERo Therapeutics Completes Series D Stock Issuance - TipRanks
CERO Expands Series D Preferred Stock Offering to Raise Capital - GuruFocus
CERo Therapeutics issues additional Series D stock - Investing.com
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million - Nasdaq
CERo Therapeutics Lands $3M Series D Extension as CAR-T Cancer Trial Shows Promise - Stock Titan
CERo Therapeutics regains Nasdaq compliance - MSN
Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance
CERo Therapeutics secures key patents for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Expands Leadership with New Executive Roles - TipRanks
Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) - Insider Monkey
CERO Therapeutics Expands Patent Portfolio with New U.S. and Eur - GuruFocus
CERo Therapeutics secures key patents for cancer therapy - Investing.com Australia
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 - The Globe and Mail
CERo Therapeutics Holds 18 Patents and Applications Expanding Immunotherapy Portfolio - Nasdaq
CERo Therapeutics Secures 18 Global Patents for Revolutionary Cancer-Fighting Cell Therapy Technology - Stock Titan
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial - MSN
CERo Therapeutics (NASDAQ:CERO) Rating Lowered to “Hold” at D Boral Capital - Defense World
CERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital - Defense World
CERo Therapeutics begins phase 1 trial for leukemia treatment By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.47 amid market challenges By Investing.com - Investing.com South Africa
CERO Initiates Phase 1 Trial for CER-1236 in Acute Myeloid Leuke - GuruFocus
0.39%
0.42%
자본화:
|
볼륨(24시간):